Skip to main content
  • European Experience Using Lotus Edge Shows Satisfactory Short-Term Outcomes but High Pacemaker Rates

    Boston Scientific has since retired the Lotus Edge THV

    A study of transcatheter aortic valve replacement (TAVR) procedures with the Lotus Edge transcatheter heart valve (THV) in 18 European centers yielded satisfactory short-term safety and efficacy, favorable hemodynamic results and low rates of paravalvular leak (PVL) in patients with complex anatomy. However, the rate of new permanent pacemaker (PPM) implantations remained high, according to the study, which was published Monday in JACC: Cardiovascular Interventions.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details